Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive disease with a poor prognosis in which
nuclear factor kappa B (
NF-kappaB) is thought to play a role. This study explored the effects of
histone deacetylase inhibitors (HDACIs)
MS-275,
suberoylanilide hydroxamic acid (SAHA), and
LBH589 on both human T-cell lymphotropic virus type I (HTLV-1)-infected T cells (MT-1, -2, -4, and HUT102) and freshly isolated ATL cells harvested from patients. HDACIs effectively inhibited the proliferation of these cells. For example,
MS-275, SAHA, and
LBH589 effectively inhibited the proliferation of MT-1 cells with ED(50s) of 6microM, 2.5microM, and 100nM, respectively, as measured by 3-(4,5-dimethylithiazol-2-yl)-2,5-diphenyl tetrazolium
bromide assay on day 2 of culture. In addition, HDACIs induced cell cycle arrest at the G2/M phase and apoptosis of HTLV-1-infected T-cells in conjunction with regulation of apoptosis-related
proteins. Electrophoretic mobility shift assay showed that exposure of HTLV-1-infected T-cells to HDACIs for 48h inhibited formation of the
NF-kappaB/
DNA binding complex. Moreover, we found that HDACIs accumulated
NF-kappaB and inhibitory subunit of
NF-kappaB in the cytoplasm in conjunction with the down-regulation of
NF-kappaB in the nucleus, suggesting that HDACIs blocked nuclear translocation of
NF-kappaB. Based on these findings, we believe HDACIs can be useful for treating patients with ATL or other types of
cancer in which
NF-kappaB plays a role.